Highlights d Generated 2.8 Å X-ray crystal structure of the IL-33-ST2-IL1RAcP signaling complex 
In Brief IL-1RAcP is the co-receptor shared by most cytokines in the IL-1 family. G€ unther et al. demonstrate that although IL1RAcP interacts with different cytokinereceptor pairs through a conserved architecture, it uses starkly different strategies to engage IL-1b and IL-33 and form signaling-competent ternary complexes.
INTRODUCTION
The interleukin-1 (IL-1) family comprises 11 cytokines that are central regulators of immunity and inflammation. Agonist cytokines of this family bind their cognate receptors (e.g., the IL-1 receptor I [IL-1RI, also known as IL-1R1] for the prototypical agonist cytokines IL-1a and IL-1b) and subsequently recruit a co-receptor, most commonly IL-1 receptor accessory protein (IL-1RAcP, also known as IL-1R3), to form ternary complexes. The structural basis of the formation of IL-1b signaling complexes has been well defined by numerous X-ray crystal structures of this ternary complex comprising a cytokine, cognate receptor, and co-receptor (Thomas et al., 2012; Wang et al., 2010) . Cytoplasmic Toll/IL-1 receptor (TIR) domains attached to the cognate and co-receptors are brought into close proximity by these extracellular binding events, resulting in signal transduction. Because of the potency of the cellular responses of IL-1 cytokines, several layers of negative regulation exist to inhibit the effects of these responses, including (1) antagonist cytokines (e.g., IL-1 receptor antagonist ), which bind to cognate receptors but do not recruit co-receptors; and (2) decoy receptors (e.g., IL-1RII or soluble suppression of tumorgenicity ST2 [also known as sST2, IL-1R4, IL-1RL1, T1, or IL-33R]), which lack trans-membrane regions and/or cytoplasmic TIR domains.
IL-33 is an agonist cytokine that binds its cognate receptor, ST2, and recruits the same co-receptor, IL-1RAcP, as that recruited by IL-1b. The crystal structure of the binary IL-33-ST2 complex (but not the ternary IL-33-ST2-IL-1RAcP complex) has been reported (Liu et al., 2013) . No antagonist IL-33 cytokine exists, and IL-33 signaling is instead negatively regulated primarily by sST2 (which acts as a decoy receptor; Hayakawa et al., 2007) , as well as by IL-33 oxidation and cleavage by caspases (Cayrol and Girard, 2009; L€ uthi et al., 2009) . IL-33 also contains an N-terminal nuclear localization domain that typically retains the cytokine in the nucleus where it is bound to chromatin (Carriere et al., 2007) ; the deletion of this domain causes IL-33-specific systemic inflammation (Bessa et al., 2014) . With no signal sequence for secretion, IL-33 is instead released from damaged or necrotic endothelial and epithelial cells and acts as an alarmin to alert the immune system to tissue damage . Inflammatory proteases from neutrophils and mast cells process full-length IL-33 into mature forms, equivalent in molecular weight to other mature IL-1 family cytokines, with increased receptor binding and signaling activity (Lefranç ais et al., 2014; Lefranç ais et al., 2012) .
IL-33 is predominantly expressed by epithelial, endothelial, and fibroblast cells (Liew et al., 2016) . Because ST2 is presented on the surfaces of many immune cells, IL-33 has pleiotropic effects in health and disease and has wide-ranging roles in tissue and metabolic homeostasis, infection, inflammation, cancer, and neurological disorders. Originally thought to activate only T helper 2 (Th2) and mast cells (Schmitz et al., 2005) , IL-33 is now known to stimulate diverse activated ST2-expressing leukocytes such as Th1 cells, regulatory T (Treg) cells, group 2 innate lymphoid cells (ILC2s), CD8 + T cells, and natural killer (NK) cells.
IL-33 stimulation of Th2 cells, Treg cells, and ILC2s induces their proliferation, survival, and migration, as well as their production of the type 2 immune mediators IL-4, IL-5, and IL-13 (Lott et al., 2015; Molofsky et al., 2015) . The type I immune mediator interferon-g (IFN-g) is produced by Th1 cells, CD8 + T cells, and NK cells in response to IL-33 (Bonilla et al., 2012) . Collectively, these signaling events drive a vast network of immune and inflammatory processes. Although IL-33 is constitutively expressed at high levels, it can be further upregulated during inflammation. Accordingly, IL-33 signaling plays a central role in clearing infections by helminths, protozoa, fungi, bacteria, and viruses (Liew et al., 2016) . As a potent mediator of inflammation, IL-33 can be responsible for a variety of chronic inflammatory disorders. IL-33 is deleterious in asthma, allergy, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, age-related macular degeneration, and periodontitis. Conversely, IL-33 confers beneficial effects in cardiovascular diseases, obesity, diabetes, and uveitis (Liew et al., 2016) .
Given the central involvement of IL-33 in these diseases, there is considerable interest in the development of biologics for modulating its activity. IL-1 signaling has already been successfully targeted in a number of auto-inflammatory conditions through the use of several biologics, including antagonist cytokines, decoy receptors, and antibodies (Dinarello et al., 2012) . Unlike IL-1, no IL-33 signaling complex includes both ST2 and the shared co-receptor IL-1RAcP, hampering the tailored development of biologics for the treatment of IL-33-mediated pathologies. Here, we present the X-ray crystal structure of the ternary IL-33:ST2:IL-1RAcP signaling complex, as well as comprehensive mutational, biophysical, and functional analyses of the IL-33 and IL1b signaling complexes. Our data define the molecular basis of IL-1RAcP receptor sharing and show that although IL-1RAcP uses the same structural motifs to engage different cytokine-receptor pairs, the mechanisms by which signaling-competent ternary complexes form are distinct.
RESULTS

Signaling Complexes in the IL-1 Family Adopt a Conserved Supramolecular Architecture
We crystallized the ternary complex of murine IL-33:ST2:IL1RAcP ( Figure 1A and Table S1 ) and determined its 2.8 Å resolution structure. The overall structure resembled those of other ternary complexes from the IL-1 family (Thomas et al., 2012; Tsutsumi et al., 2014; Wang et al., 2010) (Figure 1B ). The three ST2 immunoglobulin (Ig) domains wrapped around IL-33. This binary complex was then bound by the co-receptor IL-1RAcP, whose second and third Ig domains (D2 and D3, respectively) engaged a combined interface between ST2 and IL-33. D1 domains from neither ST2 nor IL-1RAcP participated in complex formation.
Although our murine ternary IL-33:ST2:IL-1RAcP complex is similar to the binary human IL-33:ST2 complex (Liu et al., 2013) with an overall root-mean-square deviation (RMSD) of 1.46 Å (Figure S1A ), the orientation of the three domains of ST2 differed between the two complexes, and subsequently, the structures of the individual domains were more conserved than that of the entire binary complex, as indicated by lower RMSD values of the individual domains and cytokine (D1D2: 0.96 Å ; D3: 0.94 Å ; IL-33: 1.1 Å ) than of the entire complex ( Figure S1A ). D1D2 and D3 of ST2 were shifted in relation to IL-33 upon IL-1RAcP binding ( Figure S1A ). The ST2 D1 and D2 domains were rotated 4.5
, bringing the backside of ST2 closer to IL-1RAcP (e.g., human ST2 residue D169 [hST2 D169 ], which is mouse mST2 D175 , moved 2 Å toward IL-1RAcP), and the ST2 D3 domain was rotated 9
, causing a shift of D3 along the IL-1RAcP-D3 interface (e.g., hST2 L233 [mST2 I238 ] moved 4 Å along IL-1RAcP) ( Figure S1A ).
The most substantial differences existed at the IL-33:IL1RAcP interface. The loops connecting b strands 4 and 5 (b4-5 loop) and 11 and 12 (b11-12 loop) were absent in the IL-33:ST2 binary structure, most likely as a result of their inherent flexibility in the absence of IL-1RAcP; these loops also appear to be unstructured in the nuclear magnetic resonance (NMR) structure of IL-33 (Lingel et al., 2009 ). In the ternary complex structure, conversely, loops b4-5 and b11-12 were both ordered, and the latter made contacts with both IL-1RAcP (201 Å 2 buried surface area [BSA] ) and ST2 (54 Å 2 ) ( Figure 1A ). Similar movements were observed between the IL-1b:IL-1RI binary (Vigers et al., 1997) and the IL-1b:IL-1RI:IL-1RAcP ternary complex structures. The overall RMSD of IL-1b:IL-1RI was 1.21 Å , but the relative orientation of the individual domains differed, as evidenced by lower RMSD values of individual domains (D1D2: 0.78 Å ; D3: 0.59 Å ; IL-1b: 0.8 Å ). However, the rotations of the receptor domains differed between the IL-1b and IL-33 complexes ( Figure S1B ). The IL-1RI D1 and D2 domains shifted on the upper surface of IL-1b by a rotation of 3.7 , in effect causing an upward shift of these domains in relation to the IL-1RAcP binding site (e.g., IL-1RI N154 was displaced by 1.8 Å ). The IL-1RI D3 domain rotated around 6.6 toward IL-1RAcP, shifting the receptor D3 domain along the co-receptor and displacing IL-1RI E234 by 3.2 Å . These movements allowed for a closer apposition of the D3 domains of both receptors.
In the crystallographically defined ternary complexes in the IL-1 family, the total BSA at the interface formed by the co-receptor (e.g., IL-1RAcP or IL-18Rb) and the binary complex of interleukin and primary receptor (e.g., IL-33:ST2, IL-1b:IL-1RI, IL-1b:IL-1RII, or IL-18:IL-18Ra) varied from 2,380 Å 2 for the IL-18 complex to 3,718 Å 2 for the IL-33 complex ( Figure 1C ). Although the IL-33:ST2 complex exhibited the largest combined interface with IL-1RAcP, the BSA contributed by the cytokine itself was the least out of all analyzed complexes. Despite this, a conservation of the size of the interface between IL-1RAcP and the individual binary complexes was evident. In all five complexes, the differences in BSA derived mainly from the contribution of the receptor D3 domain. Superposition of the ST2 and IL-1RI D3 domains within their respective ternary complexes indicated that they were rotated with respect to each other by 64 and thereby engaged the IL-1RAcP D3 domain with a different face of the cognate receptor D3 (Figure 1D) . This was not caused by IL-1RAcP binding given that the ST2 D3 domain exhibited the same orientation in the binary complex ( Figure S1A ). Because Ig domains are ellipsoidal, this enabled the broader side of ST2 D3 to engage the common surface of IL-1RAcP D3, resulting in a larger interface than for the IL-1b complex.
Despite these differences, we observed common principles in how the binary cytokine-receptor complex engaged the shared co-receptor IL-1RAcP. First, the loop connecting strands c and d of the D2 domain (c2-d2 loop) resided at the intersection of all three binding partners and exhibited conformational plasticity to accommodate differences in the binary complexes of distinct primary receptors and cytokines ( Figure S1C ). In the IL-1b:IL-1RI:IL-1RAcP and IL-33:ST2:IL-1RAcP complexes, the c2-d2 loop engaged both the cytokine and receptor through an extensive hydrogen-bonding network (Figures 2A-2C and Figure S2 ). Second, a hydrophobic patch on the receptor side engaged IL1RAcP I155 ( Figures 2D and 2E ). In the IL-1b complex, it made mainly hydrophobic interactions with the two side chains of IL-1RI I182 and IL-1RAcP I155 ( Figure 2E ). In contrast, in the IL-33 complex, the side chain of ST2 D175 made van der Waals contacts with the side chain of IL-1RAcP I155 and formed an additional hydrogen bond to the main chain of the same residue ( Figure 2D ). Third, the IL-1RAcP D2D3 linker engaged the cognate receptors ( Figures 2F and 2G ). In the IL-1b complex, IL-1RAcP K238 bound IL-1RI D120 through a salt bridge and IL-1RI N168 through a hydrogen bond ( Figure 2G ). Moreover, it made van der Waals contacts with IL-1RI A118 . In addition, there was a contact with the IL-1RI-D2:D3 linker via van der Waals contacts between IL1RAcP N239 and IL-1RI P206 . Similarly, in the IL-33 complex, IL1RAcP K238 formed salt bridges with ST2 D132 and ST2 E210 and between IL-1RAcP D239 and ST2 K133 ( Figure 2F ). There was also a linker-linker contact through van der Waals contacts between the side chain of IL-1RAcP D239 and ST2 F213 .
These three common features involved the D2 modules of the receptor and co-receptor. The rotation of the ST2 D3 domain in relation to IL-1RAcP resulted in a different interface ( Figure 1D resulting in different engagement of the two receptor D3 surfaces. These receptor surfaces were of a different chemical nature. Although IL-1RAcP H246 and IL-1RAcP Y269 engaged IL-1RI:D3 through polar interactions (salt bridges to IL-1RI R208 and IL-1RI D304 ) ( Figure 2I ), they used hydrophobic interactions to engage ST2 M215 , ST2 V218 , ST2 T220 , and ST2 M285 ( Figure 2H ).
In summary, the IL-33:ST2:IL-1RAcP structure, together with previously determined complex structures involving IL-1RAcP, revealed the conserved usage of structural motifs that can engage diverse cytokine-receptor binary complexes on the coreceptor side through different physicochemical strategies.
Mouse and Human IL-33 Ternary Signaling Complexes Are Indistinguishable in Solution
Mouse and human IL-33, ST2, and IL-1RAcP sequences exhibit a high degree of conservation ( Figure S3 ). To determine whether this translates to similar tertiary and quaternary structures between these sequences, we used small-angle X-ray scattering (SAXS) to analyze the complexes of both human and murine IL-33:ST2:IL-1RAcP, as well as human IL-1b:IL-1RI:IL-1RAcP, in solution. From the scattering profiles ( Figure 3A ), we calculated pairwise distance distributions ( Figure 3B ) and generated molecular envelopes of the complexes in solution ( Figure 3C ). The crystal structures of the human IL-1b:IL-1RI:IL-1RAcP and murine IL-33:ST2:IL-1RAcP complexes were superimposable with the respective envelopes derived from SAXS ( Figure 3C ). Moreover, the SAXS-derived molecular envelope of the human IL-33:ST2:IL-1RAcP complex was superimposable with a model based on our crystal structure of the murine complex ( Figure 3C ), confirming that the mouse and human IL-33:ST2:IL-1RAcP complexes are largely indistinguishable in solution. Thus, we performed all additional mutational, biophysical, and functional analyses of the IL-33 signaling complex by using human proteins.
IL-33:ST2 and IL-1b:IL-1RI Engage Their Shared Coreceptor, IL-1RAcP, Differently To interrogate these interfaces in both IL-1b:IL-1RI:IL-1RAcP and IL-33:ST2:IL-1RAcP complexes in more detail, we used protein painting, which involves adding dye molecules that bind protein surfaces with high affinity to a protein complex as well as to its individual components. The bound dye molecules block protease sites, and comparing the generated peptide pattern of the complex with the individual proteins by mass spectrometry can reveal the interface of the complex. Previously, protein painting had been applied to identify a region within the interface of the IL-1b:IL-1RI:IL-1RAcP complex; this region was subsequently targeted with a peptide that disrupted complex formation and signaling .
Although the contact sites from protein painting generally confirmed the binding mode of IL-1RAcP with its binary complexes as seen in the crystal structures, these sites were distinctly distributed (Figure 4) . For IL-1RAcP in complex with IL-1b:IL-1RI, we confirmed IL-1RAcP R306 as the single site identified by protein painting . On the receptor side, IL-1RI K178 and IL-1RI R180 were close to the three-way interface around the IL-1RAcP c2-d2 loop ( Figure 2C ). As a confirmation of this interface, we identified IL-1b K138 within the cytokine b11-12 loop. Moreover, we found IL-1b K55 in the b4-5 loop and IL-1b K109 in the b8-9 loop to be affected by co-receptor binding. In contrast, in the IL-33:ST2:IL-1RAcP complex, we identified several additional residues in IL-1RAcP as being affected by IL-33:ST2 binding. Residues of IL-1RAcP, including R157, K216, K343, and K346, formed an extended interface arranged along the spine of the co-receptor ( Figure 4B ). This also corresponded to the pattern observed on ST2, which had five affected residues. Whereas ST2K163 engaged the IL-1RAcP c2-d2 loop ( Figure 2B ) at the top of the complex, residues K127, K130, K241, and K312 formed an extended interface running down to the D3 domain, which aligned with IL-1RAcP residues R157, K216, K343, and K346 in the ternary complex. No contact regions with IL-1RAcP were identified in IL-33, and likewise, IL1RAcP R306 was not affected by IL-33:ST2 binding. Altogether, the protein-painting analysis suggests that the engagement of the cytokine in the IL-33:ST2 complex is distinct from that in the IL-b:IL-1RI complex.
Kinetic Analysis of Co-receptor Engagement Revealed Differential Usage of Common Motifs in IL-1 and IL-33 Complexes
To gain a more detailed and dynamic view of the interactions between human IL-1b and IL-33 ternary complexes in solution, we conducted hydrogen-deuterium exchange mass spectrometry (HDX-MS), in which the kinetic analysis of deuterium incorporation into the protein complex allows the determination of intrinsic protein flexibility, which can change upon complex formation. In each case, we compared the HDX patterns of the ternary complexes with those of the binary receptor-cytokine complexes and IL-1RAcP alone ( Figure 5A ). Overall, the data fit the models from the crystal structures well. The interface areas between IL1RAcP and the two binary complexes contained those peptides that were most protected from deuteration. The peptides with the largest differences between the two states (IL-1RAcP bound versus unbound) on the receptor side were found in the hydrophobic patch region of ST2 (peptide 166-172) and IL-1RI (peptide 129-142, which lay directly below the b strand and contacted the hydrophobic patch on the co-receptor side) (Figure 5B ). An IL-1RI peptide containing the residues closest to IL-1RAcP in the crystal structure around IL-1RI I182 ( Figure 2E ) could not be identified during the analysis.
Beyond these similarities of the complexes, peptides derived from cytokine loops b4-5 and b11-12 displayed different exchange behavior. Both IL-1b and IL-33 b4-5 loops exhibited reduced exchange in their respective ternary complexes only at later time points, which indicated that the formation of the ternary complex had some indirect effects on the dynamic behavior of this region ( Figure 5C ). However, the IL-33 b4-5 loop exhibited a higher percentage of deuteration overall, indicating that this region was more amenable to exchange and suggesting that the b4-5 loop of IL-33 was just as flexible in the ternary complex as it was in both its binary complex (Liu et al., 2013) and unbound (Lingel et al., 2009) forms. In contrast, the b11-12 loop in IL-1b (peptide 134-146) exhibited only half as much deuteration in the ternary complex as in the binary complex at the earliest time point (Figure 5C ), indicating that this loop was shielded from greater exchange upon binding the coreceptor and verifying that this region contributed to the engagement of IL-1RAcP ( Figure 2C ). IL-33 exhibited markedly different behavior. Peptide IL-33(250-258), including two-thirds of the b11-12 loop (IL-33(251-261)), was already highly deuterated at the earliest time point, indicating accessibility of this region even in the ternary complex, and accordingly, this region was not influenced by co-receptor binding ( Figure 5C ). In contrast, peptide , including the remainder of the b11-12 loop, was destabilized in the ternary complex, which showed more HDX than the binary complex ( Figure 5C ). This suggests that IL-1RAcP binding imposed a change in secondary structure here, an effect not seen for any other region in either complex. We observed similar behavior between peptides IL1RAcP (182) (183) (184) (185) (186) (187) (188) (189) (190) (191) (192) (193) (194) (195) (196) and , which both contain the peptide in the c2-d2 loop ( Figure 5D ) that bound to the cytokine b11-12 region ( Figures 2B and 2C) . Binding of IL-1b:IL-1RI and also of IL-33:ST2 to IL-1RAcP reduced exchange, albeit to a larger extent in the former complex. This indicates that this loop engaged the complex of IL-33:ST2 and IL-1b:IL-1RI in a fashion similar to that seen in the crystal structures ( Figures 2B and 2C) ; however, it made more stable contact in the IL-1b complex, as evidenced by reduced deuterium exchange for peptide even at the earliest time point. In contrast, the same peptide in the IL-33 ternary complex exhibited no significant differences for the two earliest measurements. In addition, the observed differences could be attributed to the first half of the peptide because peptide exhibited similar behavior in both ternary complexes ( Figure 5D ).
The peptide with the highest percentage of protection of hydrogen-deuterium exchange in both complexes was IL1RAcP(150-156) ( Figure S4C ), which included IL-1RAcP I155 in the hydrophobic patch region of IL-1RAcP ( Figures 2D and  2E ). This peptide exhibited exchange behavior with EX1 kinetics (Weis et al., 2006 ) (i.e., the complex dissociation rate was much slower than the exchange rate), which resulted in bimodal mass spectra for this peptide ( Figure S4D ). Deconvolution of the individual components, which allowed for the determination of the fraction of dissociated-and thus exchanged-peptides ( Figure 5E ) (Guttman et al., 2013) , suggests that the IL-33 ternary complex dissociated faster (halflife of 10 min) than the IL-1b complex (half-life of >30 min). When we measured the binding of both binary complexes to IL-1RAcP by surface-plasmon resonance (SPR) spectroscopy (Table S2) , we found that the dissociation rate was faster for the IL-33 ternary complex (2.7 3 10 À4 s À1 ; half-life of 26 min) than for IL-1b (4.7 3 10 À4 s À1 ; half-life of 43 min).The HDX-MS analysis confirmed that IL-1RAcP uses similar motifs to engage IL-1b:IL-1RI and IL-33:ST2 but employs these differently in each complex.
IL-33 Signal Initiation Is Less Cytokine Dependent Than Is IL-1b
To gain a more detailed understanding of the distribution of binding energy within the interfaces of the human IL-1 and IL-33 signaling complexes, we undertook a comprehensive alaninescanning mutagenesis analysis (Cunningham and Wells, 1989) in which we generated a total of 76 mutants and measured their effects on the binding of the binary complexes to IL-1RAcP by SPR ( Figure 6 , Figures S5 and S6 , and Table S2 ). This allowed us to clearly identify common IL-1RAcP-binding hotspots that were used for both IL-1b:IL-1RI and IL-33:ST2. In both complexes, IL-1RAcP I155A contributed approximately 4 kcal/mol and IL-1RAcP N189A provided more than 2 kcal/mol of binding energy. These residues were central to two of the common structural features of these signaling complexes ( Figures 2B-2E ). In contrast to these commonalities, we identified additional hotspots that were unique to either IL-1b:IL-1RI or IL-33:ST2.
Residue IL-1RAcP Y269 in the D3 domain was important for IL-33:ST2 binding, but this same residue made a negligible energetic contribution to IL-1b:IL-1RI binding. Conversely, IL1RAcP R306 , which is a hotspot for IL-1b signaling , contributed energetically in a substantial way only to IL-1b:IL-1RI binding. Another residue previously suggested to be important for the formation of ternary complexes is IL1RAcP S205 (Wang et al., 2010) , which formed a hydrogen bond to IL-1b D145 in IL-1b ternary complexes but contacted neither IL-33 nor ST2 directly in the IL-33:ST2:IL-1RAcP structure (Figure S2C) . The binding analysis verified this observation. Mutation of IL-1RAcP S205A influenced binding to IL-1RAcP only by IL1b:IL-1RI but not by IL-33:ST2. Furthermore, only a single hotspot on IL-1RI, residue I182, faced the hydrophobic patch around IL-1RAcP I155 ( Figure 2E ). In IL-1b, several residues contributed more than 0.5 kcal/mol of binding energy to complex formation. IL-1b D54 and IL-1b K55 resided on the b4-5 loop and interacted with IL-1RAcP R306 . IL1b I106 resided on b strand 8 and made contacts with IL-1RAcP. IL-1b Q126 was part of the hydrogen-bonding network that engaged loop c2-d2 in IL-1RAcP ( Figure 2C ). Finally, IL-1b D145 , previously identified as important for the agonist function of IL-1b (Ju et al., 1991) , interacted with IL-1RAcP S205 .
In contrast to IL-1RI, which showed a very narrow spatial distribution of binding energy, ST2 exhibited a much broader distribution with more contributing residues ( Figure 6D ). Of the residues that exhibited substantial effects on binding energy, ST2 H162 and ST2 K163 coordinated loop c2-d2 of IL-1RAcP (Figure 2B) , and residues ST2 F165 , ST2 V167 , and ST2 D169 were all part of the hydrophobic patch that faced IL-1RAcP I155 (Figure 2D) . Residues ST2 F208 and ST2 L210 faced residue IL1RAcP Y269 in the D3 domain ( Figure 2H ). Also, the hydrogen bond between residues ST2 K127 and IL-1RAcP N239 in the D2D3 linker region contributed to binding ( Figure 2F ). The alaninescanning mutagenesis analysis of IL-33 revealed no pronounced hotspots ( Figure 6E ). Of all mutants that we analyzed, IL-33 D175A exhibited the largest effect on binding; it resided in the b4-5 loop and formed a hydrogen bond through its main chain to IL1RAcP S303 ( Figure S2B ).
In total, the alanine-scanning mutagenesis analysis revealed two common mechanisms in IL-1RAcP engagement: (1) the mainly hydrophobic interaction around IL-1RAcP I155 , which included a conserved hydrophobic spot on the primary receptor side, and (2) the coordination of IL-1RAcP loop c2-d2 by the cytokine and primary receptor, mainly through an extended hydrogen-bond network. However, whereas the first was equally important for IL-1b:IL-1R1 and IL-33:ST2 binding to IL-1RAcP, 
IL-33 Signaling Depends Less on Direct Cytokine-Coreceptor Interactions Than Does IL-1b Signaling
We next determined whether the observed differences in binding affinity translated to differences in signaling. We observed a significant reduction in hIL-33-mediated signaling for ST2 mutants K127A, H162A, K163A, and D169A, the latter of which exhibited the largest reduction in signaling (Figure 7 ). This was in line with the observations from the direct binding assay. However, we found that none of the interactions between the D3 domains of ST2 and IL-1RAcP had a substantially negative effect on signaling.
In accordance with the observations from the binding assay, few mutations in IL-33 had an effect on signaling. Mutations with the clearest reduction in signaling in comparison with that of wild-type IL-33 included IL-33 mutants Y129A, G174W, and L264A. Whereas IL-33 Y129A exhibited reduced ST2 activation, the corresponding mutant IL-33 Y129F showed normal activation, specifically implicating its aromatic ring in potentially stabilizing the IL-33 b11-12 loop by packing against it ( Figure 2B ). The mu- tation with the largest reduction in binding affinity, IL-33 D175A , did not show a substantial reduction in activation. However, introduction of a bulky side chain at the previous residue in the IL-33 b4-5 loop by mutation IL-33 G174W might have influenced the flexibility of this region and thereby the interaction with IL-1RAcP, although this effect was seen only in signaling but not binding. Finally, IL-33 L264A exhibited the largest reduction in signal activation. This residue did not make direct contact with IL-1RAcP. However, it sat underneath the IL-33 b11-12 loop and might have influenced its conformation ( Figure S2C ).
In contrast, in the IL-1b complex, the corresponding residue, IL-1b D145 , formed a hydrogen bond to IL-1RAcP S205 . This residue is important for IL-1b activity (Ju et al., 1991; Wang et al., 2010) (and also Figures 6C and 7B ). In the IL-33 complex, both residues were much farther apart (11.4 Å between both Ca atoms) than in the IL-1b complex (7.7 Å ). Reverting this residue in IL-33 to aspartate (IL-33 L264D ), as found in IL-1b, restored IL-33 activity ( Figure 7B ), indicating either that IL-33 can approach IL-1RAcP more closely than observed in the crystal structure to form the hydrogen bond seen in the IL-1b complex or that this residue is important for stabilization of the b11-12 loop and that IL-33 L264D can be substituted without significant effects on signaling. The b11-12 loop is one of the most divergent areas between human and murine IL-33 in both sequence and length (Figure S3 ), a quality that makes it difficult to exactly predict its molecular interactions with IL-1RAcP on the basis of the murine complex structure. To assess the potential differences, we substituted the murine b11-12 loop for the human loop in human IL-33 (IL-33 mb11-12 ) and observed a reduction in signaling. Considering that we saw an increase in flexibility in this region by HDX-MS ( Figure 5C ), the chimeric protein could have altered flexibility in this region to make productive engagement of IL1RAcP more difficult. No other IL-33 mutations of interface residues affected signaling substantially.
Mutants of IL-1b exhibited larger losses in signaling than mutants of Il-33 (Figure 7) . The same mutations that had the largest effects on binding (Figure 6 ) also showed the largest reductions in signal activation. For example, IL-1b D54A and IL-1b K55A on the b4-5 loop exhibited the largest reduction. Also, IL-1b D145A in the extension of the b11-12 loop ( Figure S2C ) exhibited reduced signaling through IL-1RI. Together, these data confirm the direct contribution of individual residues of IL-1b to signaling, whereas IL-33 signaling depended less on single residues contacting hIL-1RAcP than on an interface that was more distributed ( Figure S7 ).
DISCUSSION
Through combined structural, molecular, and functional approaches, we discerned the basis for sharing the main co-receptor in the IL-1 family, IL-1RAcP. Our data allowed us to define several conserved interaction motifs between the shared receptor IL-1RAcP and its binary cytokine-receptor complexes, including (1) loop c2-d2 of IL-1RAcP, which forms a cytokinesensor loop that engages both the cytokine and its primary receptor; (2) residue IL-1RAcP I155 , which acts as a hydrophobic hook; and (3) polar interactions between the primary receptor and the linker region between domains 2 and 3 of IL-1RAcP. Also, the D3 domains of both receptors engaged each other by using similar contact points on the co-receptor side, although they employed markedly different chemical strategies on the receptor side.
The molecular basis for receptor sharing by the IL-1 family of cytokines can be compared according to the principles governing receptor sharing for other major cytokine families. The previous comparison of the signaling complex IL-1b:IL-1RI:IL-1RAcP with the non-signaling complex IL-1b:IL-1RII:IL-1RAcP suggests the use of disparate interactions for complex formation with the exception of the hydrophobic patch around IL-1RAcP I155 and IL1RAcP I201 (Thomas et al., 2012) . With the IL-33:ST2:IL-1RAcP signaling complex, we have demonstrated that the interface contains additional shared motifs, and although overlap exists in the engagement of residues in the receptor D3 domains, the chemical nature of these interactions is distinct. Within the common g-chain cytokines, shape complementarity and stem-loop contacts between the two membrane-proximal receptor domains seem to enable receptor sharing (Wang et al., 2009) . Receptor sharing of gp130, in contrast, relies more on the recognition of different cytokine surfaces through chemically unique interactions. Additionally, within the interferon family, type I interferons engage their receptor through common anchor points (Thomas et al., 2011) . Recently, the structure of an affinityenhanced type II interferon (IFN-l) with the IFN-l-specific receptor IFN-lR1 and its co-receptor IL-10Rb, which is shared between several cytokines in the IL-10 superfamily, revealed the similar use of anchor points on the co-receptor to engage several distinct cytokines (Mendoza et al., 2017) .
Although IL-1RAcP employed a virtually unchanged interface to engage two largely distinct binary cytokine-receptor pairs, it used the same residues as anchor points. A starkly distinguishing factor was the contribution of IL-1b and IL-33 to complex stability and signaling ( Figure S7 ). Whereas IL-1b contributed almost half of the BSA to the interface with IL-1RAcP, IL-33 provided roughly a quarter, which was reflected in the energetic contributions of IL-1b and IL-33 to binding and complex stability. It appeared that the major influence of IL-33 on signaling activation occurred through stabilization of ST2 in a conformation that was compatible with IL-1RAcP binding. Indeed, the relative orientation of the primary receptor D1D2 and D3 domains was highly flexible in the absence of cytokine. For ST2, this has been shown experimentally (Liu et al., 2013) and through modeling (Yang et al., 2016) . Upon IL-33 binding, a single conformation is stabilized (Liu et al., 2013) . Although IL-1RI is similarly stabilized in a single conformation by IL-1b binding, the major influence on ternary complex formation and signaling activation in this case was proper presentation of this cytokine to IL-1RAcP by its cognate receptor, such that the cytokine could be involved in nearly all important interactions. In contrast to the cognate receptors, IL-1RAcP exhibits much less flexibility (Liu et al., 2013) , most likely because its D2 and D3 domains are closer to the linker between them (Wang et al., 2010) .
Although ST2 made extensive contacts with IL-1RAcP through its D3 domain, and although these contacts proved to be important for complex stability, they appeared to be unimportant for signaling in our assays. At least in the context of the full-length receptors, the binding interface formed in the membrane-distal part of the receptor complex exhibited elevated importance, meaning that the restricted diffusion of the full-length receptor in the cell membrane might compensate for the affinity loss that was measured for the soluble proteins. Also, we almost exclusively measured the effect of single mutations, whereas combinatorial mutants might lead to more noticeable changes in signaling. In other receptor systems, changes in binding affinities likewise do not always correlate with signaling outcomes. Similar to IL-4 variants (Junttila et al., 2012) , IL-13 variants engineered to span several orders of magnitude of affinity reveal a ''buffering zone'' where increases in complex stability do not correlate with increased signaling potency (Moraga et al., 2015) . Modeling suggests that receptor endocytosis becomes the rate-limiting step for activation (Moraga et al., 2015) in these cases.
Together with the observation that the region around IL1RAcP I155 exhibited a dissociation rate of the complex on the same timescale as the overall rate measured by SPR, the negligible contribution of IL-33 to co-receptor binding suggests that a stepwise process for the formation of ternary complexes leads to productive signaling. First, the cytokine binds its primary receptor, thereby stabilizing the arrangement of its D1D2 and D3 domains in an IL-1RAcP-receptive manner. Then, this binary complex engages IL-1RAcP, most likely through initial long-range electrostatic interactions (Selzer et al., 2000) . Subsequently, the hydrophobic hook around IL-1RAcP I155 engages the corresponding patch on the receptor side before the cytokine-sensor loop (IL-1RAcP c2-d2 loop) binds at the seam of the cytokine and primary receptor. This causes the D3 domains to zipper up. These binding steps ultimately cause the intracellular receptor TIR domains to be positioned closely enough to form a platform for MyD88 recruitment and signal initiation through the Myddosome (Vyncke et al., 2016) .
The antagonistic activity of IL-1Ra can be attributed at least in part to its distinct loops facing the co-receptor binding site, and the swapping of these loops into IL-1b drastically reduces the affinity of a binary complex to IL-1RAcP. This highlights the importance of the IL-1 agonist cytokine in recruitment of IL-1RAcP. In contrast, no antagonistic cytokine has been described to directly counteract IL-33 signaling. Given that IL-33-mediated signal activation relies mainly on the stabilization of ST2, this is expected. For IL-33, the main regulation of cytokine signaling on the receptor level happens through the alternatively spliced receptor sST2, which acts as a decoy receptor. In contrast, at least one bona fide antagonist, IL-36Ra, exists for the IL-36 subfamily, the third set of IL-1RAcP-dependent cytokines in the IL-1 family (G€ unther and Sundberg, 2014; Towne et al., 2011) , and we expect that in these cases the agonistic cytokines IL-36a, IL36b, and IL-36g will also make larger contributions to co-receptor binding than will IL-33.
We focused our comparison of IL-33:ST2 to IL-1b:IL-1RI because these represent the biophysically best-characterized molecules in the IL-1 family. Biologically, however, IL-1a is more closely related to IL-33 than to IL-1b. Like IL-33, IL-1a is recruited to the cell nucleus and only released upon cell stress, when it acts as an alarmin (Rider et al., 2013) . And like IL-33, IL-1a has activity in its precursor form, but its activity is augmented by protease processing. Whether this relationship extends to the molecular mechanism by which the IL-1a signaling complex is formed remains to be seen. IL-37, another IL-1 cytokine with nuclear translocation, has anti-inflammatory properties via interaction with IL-18Ra and SIGIRR (IL-1R8) (Nold-Petry et al., 2015) . SIGIRR has also been demonstrated to negatively regulate IL-33:ST2 signaling (Bulek et al., 2009) , raising the intriguing possibility that IL-33 can also recruit SIGIRR as an alternative co-receptor to negatively regulate inflammation.
Evolution of the IL-1 family provides insight into distinct dependencies on antagonistic cytokines or decoy receptors. IL-33 evolved with placental mammals, given that it is not found in birds, and is an evolutionarily younger protein (Sattler et al., 2013) than IL-1b. In contrast, ST2 orthologs have been found in mammals and in both birds and fish, indicating a more ancient role independent of IL-33. Moreover, there is evidence of sST2 function independent of IL-33 (e.g., in liposaccharide-induced monocyte and dendritic cell activation; Nagata et al., 2012; Takezako et al., 2006) , and full-length ST2 has been shown to inhibit TLR4 signaling via recruitment of commonly used adaptor proteins containing TIR domains (Brint et al., 2004) . With no antagonistic cytokine for ST2 and only a single agonistic cytokine available, no evolutionary pressure exists for IL-1RAcP to distinguish between different ST2-bound cytokines, potentially explaining why IL-33-mediated signal activation depends more on ST2 than on IL-33. In contrast, IL-1RI and IL-36R each have several agonists and at least one antagonist, and thus cytokine contributions dominate.
Finally, IL-33 signaling is an attractive therapeutic target for many indications (Liew et al., 2016) . Our results suggest that targeting IL-33 directly might prove less effective than targeting its cognate or co-receptors. Moreover, the identification of common and distinct hotspots for the binary complexes of IL-1b:IL-1RI and IL-33:ST2 on IL-1RAcP will help enable the targeted development of biologics that could block these signaling pathways either simultaneously or independently, depending on the desired clinical outcome.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
For protein expression in E. coli, strain BL21(DE3)pLysS was used. Transformed cells were grown in shaker flasks in LB medium at 37 C until OD600 of 0.6, temperature was reduced to 18 C and protein expression induced by addition of 0.1 mM IPTG. Cells were harvested after 18 hr and kept frozen until protein purification.
For protein expression in HEK293T cells, cells were grown in shaker flasks in Freestyle F17 medium (Thermo Fisher Scientific), supplemented with GlutaMAX and Geneticin at 37 C and 5% CO2. For cell signaling assays, HEK293T cells were grown under the same conditions but in static culture. Cell line identity was not separately verified.
METHOD DETAILS
Plasmids and Proteins
The proteins and genes used correspond to the following UNIPROT database entries: murine IL-33 (ID Q8BVZ5), human IL-33 (O95760), human IL-1b (P01584, containing an additional serine at the amino-terminus), murine ST2 (P14719), human ST2 (Q01638), human IL-1RI (P14778), murine IL-1RAcP (Q61730), and human IL-1RAcP (Q9NPH3). For expression of cytokines, murine IL-33 (residues 108-266), human and human IL-1b (116-269, with mutation D116S) were subcloned into plasmid pET30 containing an N-terminal hexahistidine-tag followed by a TEV protease site. All receptor DNA was subcloned into pcDNA4/TO (ThermoFisher Scientific) replacing their native secretion signal with the one found in plasmid pHLsec (Aricescu et al., 2006) , except for full length ST2 and human IL-1RAcP, which were cloned with their native secretion peptide. In particular, the following residues were subcloned: murine ST2 (26-326), human ST2 (19-321), human IL-1RI (18-336), murine , and human IL-1RAcP (1-350). After secretion peptide removal, human ST2 and murine IL-1RAcP contained three additional amino acids at their amino-termini (glutamine, threonine, and glycine). For binding studies, human IL-1RAcP was fused to human IgG 1 -Fc. Except for full length ST2, all receptor proteins contained a hexahistidine-tag at their carboxy-terminus. All point mutations were generated following the Quikchange protocol (Agilent). Clustal Omega (Goujon et al., 2010) was used for sequence alignments.
